Indication
acute myeloid leukemia
70 clinical trials
106 products
15 drugs
Product
STI-8591Product
LYT-200Clinical trial
A Phase 1 Open-label, Multi-center Study of the Safety, Pharmacokinetics (PK), and Anti-tumor Activity of LYT- 200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)Status: Recruiting, Estimated PCD: 2025-02-01
Product
VenetoclaxProduct
AzacitidineProduct
DecitabineClinical trial
A Multicenter, Open, Dose Escalation and Dose Expansion Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of STI-8591 in Subjects With Advanced Acute Myeloid Leukemia (AML)Status: Recruiting, Estimated PCD: 2025-07-01
Clinical trial
A Phase I Combination Study of CYC065 and Venetoclax in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic SyndromesStatus: Completed, Estimated PCD: 2022-11-15
Product
CYC065Clinical trial
A Controlled Multi-Arm Ph1 Study Evaluating the Safety and Feasibility of TCR Engineered Donor TCells Targeting HA1 (TSC-100) or HA2 (TSC-101) in HLA-A0201 Positive Patients Undergoing Haploidentical Allogeneic Stem Cell TransplantationStatus: Recruiting, Estimated PCD: 2024-12-01
Product
SOC + TSC-100Product
SOC + TSC-101Product
SOC TSC-101Product
APG-115Clinical trial
A Phase Ib/II Study of APG-115 Alone or in Combination With Azacitidine in Patients With Relapse/Refractory AML, CMML or MDSStatus: Recruiting, Estimated PCD: 2024-12-30
Clinical trial
A Phase 1/2, First in Human, Dose Escalation Study of MGD006, a CD123 x CD3 DART® Bi-Specific Antibody Based Molecule, in Patients With Relapsed or Refractory AML or Intermediate-2/High Risk Myelodysplastic Syndrome (MDS)Status: Terminated, Estimated PCD: 2022-07-05
Product
FlotetuzumabProduct
RuxolitinibClinical trial
Phase 1b/2 Clinical Study of the Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Profiles of CFI-400945 as a Single Agent or in Combination With Azacitidine in Patients With AML, MDS or CMMLStatus: Recruiting, Estimated PCD: 2026-01-01
Product
5-azacitidineProduct
CFI-400945Product
NKX101Clinical trial
A Phase 1 Study of NKX101, an Activating Chimeric Receptor Natural Killer Cell Therapy, in Subjects With Hematological Malignancies or DysplasiasStatus: Active (not recruiting), Estimated PCD: 2024-07-01
Clinical trial
An Open-Label Pilot Study to Evaluate the Safety and Efficacy of DVX201 NK Cells in Patients With Relapsed or Refractory AML or High Risk MDS or High Risk Overlapping Myelodysplastic / Myeloproliferative NeoplasmsStatus: Recruiting, Estimated PCD: 2024-06-01
Product
DVX201Clinical trial
A PhaseI/II, Multicenter, Open-label Clinical Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of the Menin Inhibitor BN104 in the Treatment of Patients With Relapsed/Refractory Acute LeukemiaStatus: Recruiting, Estimated PCD: 2026-06-01
Product
BN104Product
INKmuneClinical trial
A Phase I Open-Label Dose Escalation Study Of Intravenous INKmune In Patients With Myelodysplastic Syndrome With Excess Blasts (MDS-EB-1/2 - MDS-CMML 1/2) Or Acute Myeloid Leukaemia (AML)Status: Terminated, Estimated PCD: 2024-03-28
Clinical trial
A Phase I Clinical Study of Safety, Tolerability, Pharmacokinetics, and Initial Efficacy of ETH-155008 Tablets in Patients With Relapsed or Refractory Acute Myeloid Leukemia and Non-Hodgkin's LymphomaStatus: Recruiting, Estimated PCD: 2025-12-01
Product
ETH-155008Clinical trial
A Phase I, Multicenter, Open-label Study of SHR-1702 in Patients With Acute Myeloid Leukemia or Myelodysplastic SyndromeStatus: Completed, Estimated PCD: 2023-02-28
Product
JAB-8263Clinical trial
A Phase I/IIa, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-8263 in Adult Patients With Advanced Malignant TumorsStatus: Recruiting, Estimated PCD: 2024-01-01
Product
APG 2575Clinical trial
A Phase Ib/II Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML), Mixed Phenotype Acute Leukemia (MPAL), Chronic Myelomonocytic Leukemia (CMML) and Higher-Risk Myelodysplastic Syndrome (MDSStatus: Recruiting, Estimated PCD: 2024-07-30
Clinical trial
A Phase I/II Dose Escalation and Expansion Study of BST-236 Plus Venetoclax in Patients With Newly Diagnosed Acute Myeloid Leukemia Unfit for Intensive Induction ChemotherapyStatus: Recruiting, Estimated PCD: 2025-08-01
Product
SHR-1702Product
BST-236Product
venetoclaxClinical trial
A Phase 2, Open-Label, Single Arm, Multi-Center Study to Assess the Efficacy and Safety of BST-236 as a Single Agent in Adults Unfit for Intensive Chemotherapy With Relapsed or Refractory AML or Higher-Risk Myelodysplastic SyndromesStatus: Active (not recruiting), Estimated PCD: 2023-12-14
Clinical trial
A Multicenter, Open Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Initial Efficacy of XZB-0004 in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic SyndromeStatus: Not yet recruiting, Estimated PCD: 2023-02-01
Clinical trial
Safety and Efficacy Evaluation of IM23 CAR-T Cells On CD123+ AML PatientsStatus: Completed, Estimated PCD: 2020-08-01
Product
XZB-0004Product
IM23Product
CytarabineClinical trial
A Phase I/II Study of Lintuzumab-Ac225 in Older Patients With Untreated Acute Myeloid LeukemiaStatus: Completed, Estimated PCD: 2018-11-01
Product
Lintuzumab-Ac225Product
FurosemideProduct
SpironolactoneProduct
FT538Clinical trial
A Phase I, Open-Label, Multicenter Study of FT538 as Monotherapy in Relapsed/Refractory Acute Myelogenous Leukemia and in Combination With Monoclonal Antibodies in Relapsed/Refractory Multiple MyelomaStatus: Terminated, Estimated PCD: 2023-07-13
Product
FludarabineProduct
DaratumumabProduct
ElotuzumabProduct
CyclophosphamideClinical trial
A Phase 1, Open-label, Dose-escalation Trial of CD33xCD3 Bispecific Antibody in Pediatric Patients With Relapsed or Refractory Acute Myeloid LeukemiaStatus: Terminated, Estimated PCD: 2022-12-01
Product
CD33*CD3 BsAbClinical trial
A Phase 1 Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological MalignanciesStatus: Terminated, Estimated PCD: 2019-07-25
Product
evorpaceptClinical trial
A Multicenter, Pivotal Phase 3 Study of Iomab-B Prior to Allogeneic Hematopoietic Cell Transplant Versus Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia (AML)Status: Active (not recruiting), Estimated PCD: 2022-06-01
Clinical trial
A Phase 1/2 Study of Evorpacept (ALX148) in Combination With Venetoclax and Azacitidine in Patients With Acute Myeloid Leukemia (AML) (ASPEN-05)Status: Active (not recruiting), Estimated PCD: 2023-05-05
Product
AMG 397Product
DexamethasoneProduct
Iomab-BProduct
Conventional CareProduct
azacitidineClinical trial
A Multicenter, Randomized, Controlled Clinical Trial of Chidamide Combined With Venetoclax and Azacitidine in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) Who Are Not Suitable for Intensive ChemotherapyStatus: Not yet recruiting, Estimated PCD: 2027-12-30
Drug
ChidamideDrug
azacitidineClinical trial
A Prospective, Multicenter Clinical Study on The Safety and Efficacy of Avapritinib in The Treatment of Relapsed/Refractory Pediatric Core Binding Factor Acute Myeloid Leukemia (CBF-AML) With KIT MutationStatus: Recruiting, Estimated PCD: 2026-03-01
Product
AvapritinibProduct
IdarubicinClinical trial
Comparing the Efficacy and Safety of Decitabine-Fludarabine-busulfan (Dec-FB4) and Fludarabine-busulfan (FB4) as Conditioning Regimens for AML-MRStatus: Not yet recruiting, Estimated PCD: 2026-03-01
Product
BusulfanClinical trial
A Phase I-II Study to Assess Venetoclax + Azacitidine and Donor Lymphocyte Infusion in Patients With MDS or AML (Blasts < 30%) in Relapse After Allohematopoietic Stem Cell TransplantationStatus: Recruiting, Estimated PCD: 2025-09-01
Clinical trial
A Phase 1 Open-Label, Dose Escalation Study of Pitavastatin in Combination With Venetoclax in Patients With Chronic Lymphocytic Leukemia or Acute Myeloid LeukemiaStatus: Active (not recruiting), Estimated PCD: 2023-04-06
Product
PitavastatinClinical trial
A Single Arm Phase II Trial to Assess Cobicistat Boosted Venetoclax in Combination With Azacitidine (sc) in Adult Patients With Newly Diagnosed Acute Myeloid Leukaemia (AML) Who Are Not Considered Candidates for Intensive Treatment RegimensStatus: Recruiting, Estimated PCD: 2028-03-01
Product
CobicistatClinical trial
A Phase I Trial of Revumenib in Combination With 7+3 (7 Days of Cytarabine and 3 Days of Daunorubicin) + Midostaurin Induction Chemotherapy for the Frontline Treatment of NPM1 and FLT3 Mutated AMLStatus: Not yet recruiting, Estimated PCD: 2026-03-02
Product
RevumenibProduct
MidostaurinProduct
DaunorubicinClinical trial
Novel Approaches to Target MECOM/EVI1 in Acute Myeloid LeukemiaStatus: Recruiting, Estimated PCD: 2026-12-01
Clinical trial
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological MalignanciesStatus: Not yet recruiting, Estimated PCD: 2030-07-01
Drug
fludarabineDrug
cyclophosphamideProduct
CD70-CAR T cell infusionProduct
MesnaClinical trial
Efficacy of Intermediate-Dose Cytarabine Induction Regimen in Adult AMLStatus: Recruiting, Estimated PCD: 2024-12-01
Product
Daunomycin and CytarabineClinical trial
Clinical Study to Evaluate the Safety and Efficacy of iPSC -NK Cells Targeting CLL1 or CD33 in Patients With Relapsed/Refractory AMLStatus: Recruiting, Estimated PCD: 2026-03-31
Product
iPSC-NK cellsClinical trial
Phase I/II Study Augmenting TAK-659 Action in Relapsed/Refractory AML by Addition of the Proteasome Inhibitor Ixazomib: Big Ten Cancer Research Consortium BTCRC-HEM17-092Status: Terminated, Estimated PCD: 2021-09-22
Drug
TAK-659Product
IxazomibClinical trial
Graft vs Host Disease Prophylaxis in Unrelated Donor Transplantation: a Randomized Clinical Trial Comparing PTCY vs ATG (GRAPPA)Status: Recruiting, Estimated PCD: 2025-08-01
Product
ATGClinical trial
A Study of Chidamide With AZA in MRD Positive AML After TransplantStatus: Recruiting, Estimated PCD: 2026-12-01
Product
Chidamide + AzacitidineClinical trial
Phase 2 Study of Mitoxantrone, Etoposide, and Cytarabine (MEC) Plus Lenalidomide for the Treatment of Adult Patients With Relapsed or Refractory Acute Myeloid LeukemiaStatus: Completed, Estimated PCD: 2019-08-29
Product
EtoposideProduct
LenalidomideProduct
MitoxantroneClinical trial
Open-label, Phase 2 Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid LeukemiaStatus: Recruiting, Estimated PCD: 2025-10-01
Product
AzaCITIDineProduct
XospataClinical trial
CC-486 and Venetoclax for Acute Myeloid LeukemiaStatus: Recruiting, Estimated PCD: 2027-03-23
Product
CC-486Clinical trial
Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AMLStatus: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
Phase II Study of (Early) Combination Salvage Therapy With Venetoclax and in Intensified Decitabine in Relapsed/Refractory AMLStatus: Recruiting, Estimated PCD: 2024-12-04
Clinical trial
Phase I/II Trial of CPX-351 + Palbociclib in Patients With Acute Myeloid LeukemiaStatus: Active (not recruiting), Estimated PCD: 2024-06-01
Product
PalcociclibDrug
CPX-351Clinical trial
A Multicenter Clinical Study of Molecular Subtyping Combined With MRD-driven Remission Induction Regimen in Children and Adolescents With AML: A Phase II Cohort Study (GMCAII)Status: Recruiting, Estimated PCD: 2028-12-01
Product
HomoharringtonineProduct
SorafenibProduct
GilteritinibClinical trial
AGORA-1 /ALFA 2100 Study : A Phase 2 Study of Gemtuzumab Ozogamicin (GO)-Gilteritinib Combination in Adults With FLT3-ITD Relapse/Refractory (R/R) AMLStatus: Recruiting, Estimated PCD: 2027-03-15
Product
Gemtuzumab ozogamicinClinical trial
Cord Blood Transplantation in Children and Young Adults With Hematologic Malignancies and Non-malignant DisordersStatus: Recruiting, Estimated PCD: 2025-12-20
Product
ClofarabineClinical trial
Primary Comparison of Liposomal Anthracycline Based Treatment Versus Conventional Care Strategies Before Allogeneic Stem Cell Transplantation in Patients With Higher Risk MDS and Oligoblastic AMLStatus: Recruiting, Estimated PCD: 2026-03-01
Clinical trial
A Phase II Prospective Study "GFM-DACORAL-DLI" ASTX727 and Donor Lymphocyte Infusions After Allogenic Stem Cell Transplantation in Very High Risk MDS or AML PatientsStatus: Active (not recruiting), Estimated PCD: 2024-04-01
Drug
ASTX727Product
Cyclosporine-AProduct
Mycophenolate MofetilProduct
Cord Blood GraftClinical trial
A Phase I Study of Tagraxofusp With or Without Chemotherapy in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic MalignanciesStatus: Recruiting, Estimated PCD: 2025-11-11
Product
TagraxofuspDrug
VincristineProduct
MethotrexateClinical trial
Comparison of Consolidation Strategies for Pediatric Patients With Acute Myeloid Leukemia - Results of the Randomized GATLA 8-LMA-P'07 TrialStatus: Completed, Estimated PCD: 2015-03-15
Product
ARM AProduct
ARM BProduct
HydrocortisoneClinical trial
Phase II Trial of Cardioprotective Prophylaxis With Combination of Beta Blocker and Angiotensin-Converting Enzyme Inhibitors During Intensive Chemotherapy for Patients With Newly Diagnosed Acute Myeloid LeukemiaStatus: Recruiting, Estimated PCD: 2025-01-01
Product
CardioprotectionClinical trial
Phase II, Open-Label, Prospective Study of T Cell Receptor Alpha/Beta Depletion (A/B TCD) Peripheral Blood Stem Cell (PBSC) Transplantation for Children and Adults With Hematological MalignanciesStatus: Recruiting, Estimated PCD: 2027-11-30
Drug
MelphalanDrug
VarlilumabProduct
LevetiracetamClinical trial
A Phase I/II Pilot Study of Memory-like NK Cells to Consolidate TCRαβ T Cell Depleted Haploidentical Transplant in High-risk AMLStatus: Recruiting, Estimated PCD: 2028-09-15
Drug
interleukin-2Drug
PlerixaforClinical trial
Phase 1 Study to Determine the Safety and Tolerability of Ziftomenib Combinations for the Treatment of KMT2A-rearranged or NPM1-mutant Relapsed/Refractory Acute Myeloid LeukemiaStatus: Recruiting, Estimated PCD: 2026-08-01
Product
ZiftomenibClinical trial
A Randomized Controlled Trial Comparing Outcome After Hematopoietic Cell Transplantation From a Partially Matched Unrelated Versus Haploidentical DonorStatus: Active (not recruiting), Estimated PCD: 2024-04-01
Product
Peripheral blood stem cellsDrug
FilgrastimClinical trial
Clinical Study to Evaluate the Safety and Efficacy of iPSC NK Cells Targeting CLL1 in Patients With Relapsed/Refractory AMLStatus: Recruiting, Estimated PCD: 2026-08-31
Product
CLL1 CAR-NK cellClinical trial
Blockade of PD-1 in Conjunction With the Dendritic Cell/AML Vaccine Following Chemotherapy Induced RemissionStatus: Active (not recruiting), Estimated PCD: 2023-12-01
Product
DC AML VaccineClinical trial
Phase I Study to Evaluate the Safety and Efficacy of NK Cell Therapy in Acute Myeloid Leukemia (AML).Status: Not yet recruiting, Estimated PCD: 2026-08-31
Product
CD33/CLL1 dual CAR-NK cellProduct
CyclophosphamidProduct
CD33 CAR-NKProduct
Super NK cellClinical trial
Feasibility Study of CD34 Selection for GVHD Prophylaxis Using the Automated CliniMACSStatus: Not yet recruiting, Estimated PCD: 2029-10-01
Clinical trial
A Phase 1 Study of Evaluating Preliminary Safety and Efficacy of CT101a in the Treatment of Relapsed or Refractory (r/r) AML PatientsStatus: Terminated, Estimated PCD: 2022-08-28
Product
CT101aClinical trial
Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid LeukemiaStatus: Not yet recruiting, Estimated PCD: 2026-01-30
Clinical trial
A Randomized Phase II Study Evaluating the Efficacy of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell TransplantationStatus: Recruiting, Estimated PCD: 2025-04-01
Product
Hyperbaric oxygenClinical trial
Open-label Multicenter Trial of Glivec® (Imatinib Mesylate, Formerly Known as STI571) in Combination With Chemotherapy (MTC) in Patients With Refractory or Relapsed Acute Myeloid Leukemia (AML)Status: Completed, Estimated PCD: 2010-12-01
Drug
imatinibProduct
TopotecanProduct
AraCClinical trial
A Randomised, Double-Blind, Placebo-Controlled, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of ZE46-0134 in Healthy VolunteersStatus: Recruiting, Estimated PCD: 2024-10-01
Product
ZE46-0134Product
RabeprazoleClinical trial
A Multicenter Prospective Cohort Study Study of CLAG Regimen in Acute Myeloid Leukemia Patients With First-induction FailureStatus: Not yet recruiting, Estimated PCD: 2027-08-20
Product
CLAGClinical trial
Clinical Efficacy and Safety of Adaptive Treatment of Acute Myeloid Leukemia (AML) Based on D14 MRD results-a Multicenter, Single-arm, Prospective Clinical StudyStatus: Recruiting, Estimated PCD: 2025-03-01
Drug
SelinexorClinical trial
NKG2D CAR-NK Cell Therapy for the Treatment of Patients With Relapsed and/or Refractory Acute Myeloid LeukemiaStatus: Recruiting, Estimated PCD: 2024-04-01
Product
NKG2D CAR-NKClinical trial
Individual Patient Expanded Access for Use of Gilteritinib (ASP2215) for Patient Y.A.Status:
Product
ASP2215Product
Thiotepa